Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Karyopharm Therapeutics (KPTI) over the last 11 years, with Q4 2025 value amounting to $5000.0.

  • Karyopharm Therapeutics' Exchange Rate Effect rose 12500.0% to $5000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $20000.0, marking a year-over-year increase of 28181.82%. This contributed to the annual value of $20000.0 for FY2025, which is 28181.82% up from last year.
  • Karyopharm Therapeutics' Exchange Rate Effect amounted to $5000.0 in Q4 2025, which was up 12500.0% from $2000.0 recorded in Q3 2025.
  • Karyopharm Therapeutics' 5-year Exchange Rate Effect high stood at $242000.0 for Q3 2021, and its period low was -$454000.0 during Q2 2022.
  • Moreover, its 5-year median value for Exchange Rate Effect was -$18000.0 (2024), whereas its average is -$28050.0.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Exchange Rate Effect skyrocketed by 132352.94% in 2021, and later crashed by 60937.5% in 2022.
  • Karyopharm Therapeutics' Exchange Rate Effect (Quarter) stood at -$135000.0 in 2021, then soared by 193.33% to $126000.0 in 2022, then dropped by 29.37% to $89000.0 in 2023, then tumbled by 122.47% to -$20000.0 in 2024, then soared by 125.0% to $5000.0 in 2025.
  • Its last three reported values are $5000.0 in Q4 2025, $2000.0 for Q3 2025, and $8000.0 during Q2 2025.